Drug Profile
Research programme: complement system inhibitors - Bioverativ
Alternative Names: TNT 010Latest Information Update: 25 Aug 2023
Price :
$50
*
At a glance
- Originator True North Therapeutics
- Developer Bioverativ
- Class Monoclonal antibodies
- Mechanism of Action Complement system protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 25 Aug 2023 Discontinued - Preclinical for Unspecified in USA (Parenteral)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Unspecified in USA (Parenteral)
- 08 Mar 2018 Bioverativ has been acquired by Sanofi